How a Toxicologist Manages Calcium Channel Blocker Toxicity

Calcium channel blocker toxicity causes shock by collapsing vascular tone, myocardial contractility, or both. Bedside POCUS is central to separating vasodilatory from cardiogenic physiology, and early high-dose insulin can be lifesaving when the heart is hypodynamic.

Calcium Channel Blocker Toxicity

• Loss of receptor selectivity: Massive calcium channel blocker overdose often blurs the usual dihydropyridine versus non-dihydropyridine pattern, so expect mixed vasodilatory and cardiogenic shock rather than a clean textbook phenotype.
• Shock phenotype by POCUS: Bedside cardiac ultrasound is the key early test because treatment hinges on whether the patient is hyperdynamic, hypodynamic, or mixed. We get into the ultrasound-based treatment split in the episode.
• Misleading initial presentation: Bradycardia, hypotension, hypoxia, and tachypnea can mimic MI, sepsis, or primary respiratory failure, making recent CCB starts or medication changes an important overdose red flag.
• Conservative fluid strategy: Hypotension in CCB toxicity is not primarily a volume problem, so fluids should be restrained; these patients also risk noncardiogenic pulmonary edema and accumulate large infusion volumes quickly.
• Calcium and pressor support: Early stabilization usually needs calcium plus hemodynamic support tailored to physiology, with norepinephrine for vasoconstriction and inotropes added when cardiac output is depressed.
• High-dose insulin role: High-dose insulin is the antidotal workhorse for a hypodynamic heart because it restores carbohydrate use and provides strong inotropy, even though bradycardia may improve only modestly.
• Intensive monitoring burden: HDI is a high-risk therapy that demands continuous hemodynamics, serial ECGs, frequent glucose checks, and repeated potassium monitoring. The practical monitoring cadence is worth hearing in the chapter.

References:

1. Gummin DD, et al. 2021 Annual Report of the National Poison Data System© (NPDS) from America's Poison Centers: 39th Annual Report. Clin Toxicol (Phila). 2022 Dec;60(12):1381-1643. PMID: 36602072.
2. Cole JB, et al. A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock. Clin Toxicol (Phila). 2013 May;51(4):201-7. PMID: 23530460.
3. Cole JB, et al. Vasodilation in patients with calcium channel blocker poisoning treated with high-dose insulin: a comparison of amlodipine versus non-dihydropyridines. Clin Toxicol (Phila). 2022 Nov;60(11):1205-1213. PMID: 36282196.
4. Peach M, et al. Does point-of-care ultrasonography improve diagnostic accuracy in emergency department patients with undifferentiated hypotension? An international randomized controlled trial from the SHOC-ED investigators. CJEM. 2023 Jan;25(1):48-56. PMID: 36577931.
5. Krenz JR, Kaakeh Y. An Overview of Hyperinsulinemic-Euglycemic Therapy in Calcium Channel Blocker and β-blocker Overdose. Pharmacotherapy. 2018;38(11):1130-1142. PMID: 30141827
6. Engebretsen KM, et al. High-dose insulin therapy in beta-blocker and calcium channel blocker poisoning. Clin Toxicol. 2011;49(4):277-83. PMID: 21563902
7. Kline JA, et al. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. 1993;267(2):744-50. PMID: 8246150
8. Kline JA, et al. Insulin improves heart function and metabolism during nonischemic cardiogenic shock in awake canines. Cardiovasc Res. 1997;34(2):289-98.  PMID: 9205542
9. Holger JS, et al. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol. 2011;49(7):653-8. PMID: 21819291